background A three-monthly formulation of intramuscular paliperidone palmitate has been available on the Dutch and Belgian markets since 2016.
aim To provide an overview of the indication, effectiveness and side-effects of this injectable three-monthly formulation of paliperidone and to offer considerations for clinical practice.
method A clinically-oriented literature study.
results Three-monthly paliperidone palmitate depot appears to be as effective as the monthly paliperidone depot and has the same profile of side-effects.
conclusion Three-monthly paliperidone palmitate is an effective treatment option for schizophrenia. However, future research and clinical practice need to clarify the position of this depot in the treatment trajectory.